Technology | Stents Peripheral | February 17, 2016

Biotronik, Maquet Partner to Deliver Peripheral Vascular Devices in the U.S.

Partnership coincides with FDA approval for Biotronik’s Astron iliac self-expanding stent

Biotronik, Maquet, partnership, peripheral vascular devices, U.S. market, Astron self-expanding iliac stent

February 17, 2016 — Biotronik announced a partnership with Maquet Medical Systems USA to distribute Biotronik peripheral vascular devices in the United States.

The two companies will deliver a range of Biotronik products used to treat peripheral artery disease (PAD). These include the Passeo percutaneous transluminal angioplasty (PTA) balloon family; the Fortress reinforced sheath; the Cruiser-18 guide wire; and the Astron stent, which was recently granted U.S. Food and Drug Administration (FDA) approval for the treatment of iliac artery disease. This is Biotronik’s first FDA approval for a peripheral stent product.

Atherosclerotic disease of the iliac arteries, which supply blood to the pelvic organs and much of the lower limbs, can greatly impact a patient’s overall quality of life, limiting walking ability and leading to chronic pain and even morbidity. Endovascular interventions, including angioplasty and stenting, have become the first-line approach for the treatment of patients with simple and complex peripheral atherosclerotic lesions, including challenging-to-access iliac lesions. In 2014, an estimated 176,800 patients in the United States received an iliac stent, and that number is expected to grow annually.

“The Astron stent is a proven option for treating atherosclerotic disease of the common or external iliac arteries. Results of a 12-month study of Astron demonstrated a major adverse event (MAE) rate of just 2.1 percent, which is remarkably lower than the pre-specified performance goal of 15 percent,” said Mark W. Burket, M.D., of the University of Toledo Medical Center in Ohio, and national principal investigator of the BIOFLEX-I IDE study, which evaluated the performance of the Astron stent. “Astron’s 12-month target lesion revascularization rate was also low, at 1.4 percent. Based on these excellent results, I believe that U.S. physicians and patients will welcome this new technology.”

The Astron self-expanding nitinol stent system is designed to provide the specific performance characteristics required for iliac arteries. It features a peak-to-valley stent design with S-shaped articulating connecting bars to provide multi-directional flexibility while avoiding fish-scaling in tortuous arteries. The segmented architecture and strut thickness are engineered to provide optimal chronic outward force.

Astron stents are manufactured with Biotronik’s unique proBIO coating, a silicon carbide layer that reduces metal ion release from the stent surface into the surrounding tissue.

For more information: www.biotronik.com

Related Content

Among high-risk, chronic, coronary patients who undergo angioplasty, there were no additional benefits from ticagrelor compared to the current standard of care clopidogrel. #AHA #AHA20 #AHA2020
News | Cath Lab | November 16, 2020
November 16, 2020 — The use of the more potent antiplatelet medication ticagrelor (Brilinta) was not superior to clop
A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab | October 18, 2020
October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benef
A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin capped fibrous atheroma (TCFA). #TCTconnect #TCT2020

A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin cap fibro-atheroma (TCFA).

News | Cath Lab | October 18, 2020
October 18, 2020 – Data from the...
The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions. #TCT2-0

The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions.

Feature | Cath Lab | October 16, 2020
October 15, 2020 — Shockwave Medical's Intravascular Lithotripsy (IVL) system to treat severely calcified coronary ar
Videos | Cath Lab | October 16, 2020
This is an example pf the Shockwave Medical Intravascular Lithotripsy (IVL) catheter system designed to break up heav
Videos | Cath Lab | July 15, 2020
Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, offers an over
Videos | Cath Lab | July 13, 2020
The Vieussens’ arterial ring (VAR) is a connection between the conus artery and the left anterior descending (LAD) co
News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major